| Sep 9 |
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
|
| Sep 6 |
Psyence Biomedical to acquire drug developer Clairvoyant
|
| Sep 6 |
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
|
| Aug 30 |
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
|
| Aug 19 |
Psyence Biomedical files for potential secondary stock offering
|
| Jul 31 |
Psyence enters into $25M common stock purchase agreement with White Lion Capital
|
| Jul 31 |
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
|
| Jul 25 |
Why Psyence Biomedical (PBM) Stock Is Skyrocketing
|
| Jul 24 |
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
|
| Jul 23 |
US home sales dip, Secret Service director resigns: Catalysts
|
